Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Healthcare Biotechnology
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Theratechnologies Inc > Presentation post or link?
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(197)
•••
Comment by scarlet1967on Feb 22, 2023 10:27am
104 Views
Post# 35298162

RE:RE:RE:Presentation post or link?

RE:RE:RE:Presentation post or link?

"11:00 am Case Study: A First-In-Class Peptide Drug Conjugate (PDC) Platform Targeting Sortilin (SORT1) Receptor Positive Cancers

 

Synopsis

  • Understanding why the normal function of a scavenger receptor, SORT1, can be exploited to rapidly transport novel peptide drug conjugates (PDCs) into cancer cells
  • Discussing the over expression of SORT1 in many solid tumours
  • Learn about Thera’s lead PDC candidate, TH1902, across multiple solid tumours
  • Review the potential of this novel SORT1+ platform for future developments"

 

https://worldadc-europe.com/whats-on/pre-conference-seminar-days/

Christian will be presenting at the Conjugate Conference (second year in a row)today early afternoon, last year they didn't go public with the discussions. 

Next is the ADC conference in London in March.

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities